CardioGenesis (Foothill Ranch, California), a developer of surgical products used in angina-relieving transmyocardial revascularization (TMR) and per-cutaneous myocardial channeling (PMC) procedures, reported in the latter part of December a foray into new territory with the launch of the CelleratOR system for the point-of-care preparation of autologous platelet-rich plasma.